Document:

AMENDED AND RESTATED

PROMISSORY NOTE

 

Date: June 29, 2012

 $[original principal amount]

 Ada, Michigan

 

FOR VALUE RECEIVED, the undersigned, INTERLEUKIN
GENETICS, INC., a Delaware corporation, of 135 Beaver Street, 2nd Floor, Waltham, Massachusetts 02452 (the “Company”),
promises to pay to PYXIS INNOVATIONS INC., a Delaware corporation, of 7575 Fulton Street East, Ada, Michigan 49355-0001 (“Payee”),
the principal amount of [original principal amount] Dollars ($[original principal amount]) and interest on the unpaid principal
balance at the per annum rate equal to the Index Rate until maturity (adjusted on the first day of each calendar quarter to the
Index Rate in effect on the date of adjustment) and the Index Rate plus two percent (2%) (adjusted on the first day of each calendar
quarter to the Index Rate in effect on the date of adjustment) per annum after maturity. As used in this Amended and Restated Note,
“Index Rate” means the “Prime Rate” listed in the Money Rates section of the Wall Street Journal.  The
principal of this Amended and Restated Note shall be paid in full on November 30, 2012.  Accrued interest shall be paid
on the first day of each calendar quarter until the principal balance shall be paid in full.

 

Prepayments. The Company may not
prepay the principal of this Amended and Restated Note without the prior written consent of the Payee, which may be given or withheld
in the Payee’s sole discretion.

 

Default and Acceleration. Each of
the following shall be an “event of default” under this Amended and Restated Note: (1) if default occurs in the payment
of principal or interest under this Amended and Restated Note or in the payment of any other indebtedness or obligation that the
Company now or in the future owes to Payee, as and when it shall be or become due and payable; (2) if default occurs in the performance
of any other obligation to Payee under this Amended and Restated Note, the Purchase Agreement (as defined below), the Stock Purchase
Agreement dated March 5, 2003, as amended, the Stock Purchase Agreement dated August 17, 2006, as amended, or any other agreement
that has been or in the future is entered into between the Company and Payee, in each case as may be amended from time to time,
or if there occurs any other event of default under the Purchase Agreement or any such other agreement; (3) if any warranty or
representation that the Company has made to Payee in any agreement, or if any financial statement or other document given to Payee
in connection with the transactions contemplated by the Purchase Agreement, shall have been false in any material respect; (4)
if the Company dissolves, becomes insolvent, or makes an assignment for the benefit of creditors; (5) if the Company defaults in
the payment of any other material indebtedness or performance of material obligations owed to any other party or entity; or (6)
a Change of Control of the Company. Upon the occurrence of any event of default, all or any part of the indebtedness evidenced
by this Amended and Restated Note and all or any part of all other indebtedness and obligations that the Company then owes to Payee
shall, at the option of Payee, become immediately due and payable without notice or demand. If a voluntary or involuntary case
in bankruptcy, receivership or insolvency shall at any time be begun by or against the Company or if any levy, writ of attachment,
garnishment, execution or similar process shall be issued against or placed upon any property of the Company, then all such indebtedness
shall automatically become immediately due and payable. All or any part of the indebtedness evidenced by this Amended and Restated
Note also may become, or may be declared to be, immediately due and payable under the terms and conditions contained in the Purchase
Agreement or other agreement that has been or in the future is entered into between the Company and Payee upon the terms and to
the extent provided therein.

 

    	 

    	 

    

 

Change of Control” shall mean
(a) a dissolution or liquidation of the Company, (b) a merger or consolidation in which the Company is not the surviving corporation,
(c) a merger or share exchange in which the Company is the surviving corporation but after which the stockholders of the Company
immediately prior to such merger cease to own at least 51% of the outstanding shares of the Company, (d) the sale, license, or
other transfer of substantially all of the assets of the Company, or (e) the acquisition, sale, or transfer (other than a transaction
involving primarily shares held by Payee or its affiliates) of more than 50% of the outstanding shares of the Company, whether
by tender offer, similar transaction, or newly issued stock (other than to Payee or its affiliates).

 

Purchase Agreement. This Amended
and Restated Note is given under a certain Amended and Restated Note Purchase Agreement, dated March 10, 2009 and amended on August
10, 2009, February 1, 2010, September 30, 2010 and June 29, 2012, between Payee and the Company (as may be further amended, modified
or restated, the “Purchase Agreement”), and Payee shall have all of the rights and powers set forth in the Purchase
Agreement as though they were set forth fully in this Amended and Restated Note.

 

Conversion. Payee has the right,
at its option, at any time before the payment in full of this Amended and Restated Note, to convert a portion or all of the balance
of this Amended and Restated Note into fully paid and nonassessable common stock of the Company. The number of shares of common
stock into which the balance of this Amended and Restated Note may be converted (“Conversion Shares”) shall
be determined by dividing the aggregate principal amount to be converted, together with all accrued interest to the date of conversion,
by $5.6783 (the “Conversion Price”). The Conversion Price is subject to adjustment as follows: if the Company
(1) pays a dividend or makes a distribution on its Common Stock in shares of its Common Stock; (2) subdivides its outstanding shares
of Common Stock into a greater number of shares; (3) combines its outstanding shares of Common Stock into a smaller number of shares;
(4) makes a distribution on its Common Stock in shares of its capital stock other than its Common Stock; or (5) issues by reclassification
of its Common Stock any shares of its capital stock; then the Conversion Price in effect immediately prior to such action shall
be proportionately adjusted so that the Payee may receive the aggregate number and kind of shares of capital stock of the Company
that the Payee would have owned immediately following such action if this Amended and Restated Note had been converted immediately
prior to such action. Each adjustment to the Conversion Price shall be effective immediately after the record date in the case
of a dividend or distribution and immediately after the effective date in the case of a subdivision, combination, or reclassification.

 

Before Payee shall be entitled to convert
some or all of the balance of this Amended and Restated Note into shares as provided above, it shall give written notice to the
Company of the election to convert, and shall state the amount of the balance to be converted. The Company shall, as soon as practicable
thereafter, issue and deliver to Payee a certificate for the number of shares of common stock to which Payee shall be entitled.
Such conversion shall be deemed to have been made immediately prior to the close of business on the date of the Company’s
receipt of the notice from Payee, and Payee shall be treated for all purposes as the record holder of such shares of stock as of
such date.

 

No fractional shares of stock shall be issued
upon conversion of this Amended and Restated Note. In lieu of the Company issuing any fractional shares to Payee upon conversion,
the number of shares issued shall be rounded to the nearest whole number. If the entire balance of this Amended and Restated Note
is to be converted, then Payee shall surrender this Amended and Restated Note, duly endorsed, at the office of the Company. If
only a portion of the balance of this Amended and Restated Note is converted, then the balance of this Amended and Restated Note
shall be reduced by the amount converted, with the remaining balance continuing as outstanding under this Amended and Restated
Note. Upon conversion, the Company shall, at its expense, issue and deliver to Payee a certificate for the number of shares of
such stock to which Payee shall be entitled upon such conversion (bearing such legends as are required by the Stock Purchase Agreement
dated August 17, 2006, as amended), together with any other securities and property to which Payee is entitled upon such conversion
under the terms of this Amended and Restated Note.

 

    	 

    	 

    

 

In the event of: (a) any taking by the Company
of a record of holders of any class of securities of the Company for the purpose of determining holders thereof who are entitled
to receive any dividend or other distribution, or any right to subscribe for, purchase, or otherwise acquire any shares of stock
of any class or any other securities or property, or to receive any other right; or (b) any capital reorganization, any reclassification,
or recapitalization of the capital stock of the Company or any transfer of all or substantially all of the assets of the Company
to any other person or any consolidation or merger or similar change of control transaction involving the Company; or (c) any voluntary
or involuntary dissolution, liquidation, or winding up of the Company; then the Company will mail to Payee at least ten days prior
to the earliest date specified therein, a notice specifying: (i) the date on which any such record is to be taken for the purpose
of such dividend, distribution, or right, and the amount and character of such dividend, distribution, or right; and (ii) the date
on which any such reorganization, reclassification, transfer, consolidation, merger, dissolution, liquidation, or winding up is
expected to become effective and the record date for determining stockholders entitled to vote thereon.

 

The Company shall, at all times, reserve
and keep available out of its authorized but unissued shares of common stock solely for the purpose of effecting the full conversion
of this Amended and Restated Note such number of its shares of common stock as shall from time to time be sufficient to effect
the conversion of this Amended and Restated Note. If at any time the number of authorized but unissued shares of common stock shall
not be sufficient to effect the conversion of the entire outstanding principal amount of this Amended and Restated Note, in addition
to such other remedies as shall be available to Payee, the Company will use its best efforts to take such corporate action as may,
in the opinion of its counsel, be necessary to increase its authorized but unissued shares of common stock to such number of shares
as shall be sufficient for such purposes.

 

Place and Application of Payments.
Each payment upon this Amended and Restated Note shall be made at Payee’s address set forth above or any other place that
Payee directs in writing. Payee shall apply any payment upon it first to any expenses (including expenses of collection) then due
and payable to Payee, then to any unpaid late charges, then to any accrued and unpaid interest under this Amended and Restated
Note and then to the unpaid principal balance. If the Company at any time owes Payee any indebtedness or obligation in addition
to the indebtedness that this Amended and Restated Note evidences, and if any indebtedness that the Company then owes to Payee
is then in default, then the Company shall not have any right to direct or designate the particular indebtedness or obligation
upon which any payment made by, or collected from, the Company or from which security shall be applied. The Company waives any
such right and agrees that Payee shall determine, in its sole discretion, the manner of application of any such payment, as between
or among such indebtedness and obligations.

 

Setoff. Payee shall have the right
at any time to set off any indebtedness that this Amended and Restated Note evidences and that is then due and payable against
any indebtedness that Payee then owes to the Company.

 

Remedies. Payee shall have all rights
and remedies that the law and any agreement of the Company provide. Any requirement of reasonable notice with respect to any sale
or other disposition of collateral shall be met if Payee sends the notice at least ten days before the date of sale or other disposition.
The Company shall reimburse Payee for any and all expenses, including reasonable attorney fees and legal expenses, that Payee pays
or incurs in protecting and enforcing the rights of and obligations to Payee under any provision of this Amended and Restated Note.

 

    	 

    	 

    

 

Waivers. A delay by Payee in the
exercise of any right or remedy shall not be considered a waiver of it. A single or partial exercise by Payee of any right or remedy
shall not preclude any other or future exercise of it or the exercise of any other right or remedy. A waiver by Payee of any default
or of any provision of this Amended and Restated Note shall not be effective unless it is in writing and signed by Payee. A waiver
of any right or remedy on one occasion shall not be a waiver of that right or remedy on any future occasion.

 

The Company waives demand for payment, presentment,
notice of dishonor and protest of this Amended and Restated Note and waives all defenses based on suretyship or impairment of collateral.
The Company consents to any extension or postponement of time of payment of this Amended and Restated Note, to any substitution,
exchange or release of all or any part of any security given to secure it, to the addition of any party to it and to the release,
discharge, waiver, modification or suspension of any rights or remedies against any person liable for the indebtedness that this
Amended and Restated Note evidences.

 

General. In this Amended and Restated
Note, “maturity” means the time when the entire remaining unpaid principal balance shall be or shall become due and
payable for any reason, including acceleration as provided above.

 

Applicable Law and Jurisdiction.
This Amended and Restated Note shall be governed by and interpreted according to the laws of the State of Michigan, without giving
effect to conflict of laws rules. The Company irrevocably agrees and consents that any action against the Company for collection
or enforcement of this Amended and Restated Note may be brought in any state or federal court that has subject matter jurisdiction
and is located in, or whose district includes, Kent County, Michigan, and that any such court shall have personal jurisdiction
and venue over the Company for purposes of the action.

 

Amendment and Restatement.  This
Amended and Restated Note amends and restates that certain Promissory Note dated [original issuance date], executed by the Company
and payable to the order of Payee in the principal amount of $[original principal amount] (the “Original Note”).  Upon
Payee’s acceptance of this Amended and Restated Note, the Original Note shall be deemed cancelled and of no further force
and effect; provided, however, that nothing in the foregoing shall be deemed to waive any outstanding accrued interest or other
amounts now due under the Original Note, which shall hereafter be deemed amounts due under this Amended and Restated Note.   By
its execution below, the Company hereby acknowledges and agrees to the amendment and restatement of the Original Note.

 

PAYEE AND THE COMPANY EACH IRREVOCABLY
AND UNCONDITIONALLY WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY ACTION, INCLUDING ANY CLAIM, COUNTERCLAIM, CROSS-CLAIM OR THIRD-PARTY
CLAIM (“CLAIM”), THAT IS BASED UPON, ARISES OUT OF OR RELATES TO THIS AMENDED AND RESTATED NOTE OR THE INDEBTEDNESS
THAT IT EVIDENCES, INCLUDING, WITHOUT LIMITATION, ANY CLAIM THAT IS BASED UPON, ARISES OUT OF OR RELATES TO ANY ACTION OR INACTION
OF PAYEE IN CONNECTION WITH ANY ACCELERATION, ENFORCEMENT OR COLLECTION OF THIS AMENDED AND RESTATED NOTE OR SUCH INDEBTEDNESS.

 

	INTERLEUKIN GENETICS, INC.	 
	 	 
	By:	 	 
	Name:	 
	Title:EXCHANGE AGREEMENT 

 

This Exchange Agreement
(the “Agreement”) is entered into this 29th day of June, 2012 by and among Interleukin Genetics,
Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Pyxis Innovations
Inc. (“Pyxis”).

 

WITNESSETH :

 

WHEREAS Pyxis holds
5,000,000 shares (the “Series A Shares”) of the Company’s Series A Preferred Stock, par value $0.001 per
share (the “Series A Preferred Stock”);

 

WHEREAS the parties
desire that Pyxis exchange (the “Exchange”) the Series A Shares for 5,000,000 shares (the “Series A-1
Preferred Shares”) of the Company’s Series A-1 Preferred Stock, par value $0.001 per share (the “Series
A-1 Preferred Stock”), having the rights, privileges and preferences set forth in the Certificate of Designations, Preferences,
and Rights of Series A-1 Preferred Stock and Series B Preferred Stock (the “Certificate of Designations”) set
forth on Exhibit A hereto; and

 

WHEREAS the parties
desire that the Exchange be consummated substantially contemporaneously with the closing (the “Closing”) of
that certain preferred stock equity investment (the “Series B Transaction”) contemplated between the Company
and Delta Dental Plan of Michigan, Inc.

 

NOW THEREFORE, in consideration
of the premises and of the mutual covenants and agreements contained herein, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby mutually acknowledged, intending to be legally bound the parties hereby agree as follows:

 

ARTICLE
I

EXCHANGE OF SECURITIES

 

SECTION
1.01         Authorization of Series A-1 Preferred Stock. On or prior to the Closing Date (as defined below), the Company
shall have authorized the issuance to Pyxis, on the terms and conditions set forth in this Agreement, of an aggregate of 5,000,000
shares (the “Series A-1 Shares”) of Series A-1 Preferred Stock having the rights, privileges and preferences
set forth in the Certificate of Designations.

 

SECTION
1.02         Transfer of the Series A Preferred Stock in Exchange for Series A-1 Preferred Stock. Pyxis agrees to transfer
and deliver to the Company, on the Closing Date, free and clear of any and all liens, charges, pledges or other encumbrances of
any kind or nature (“Encumbrances”), the Series A Shares to the Company and, in exchange therefor, the Company
agrees to issue and deliver to Pyxis the Series A-1 Shares immediately following the effectiveness of the Certificate of Designations
upon filing with the Office of the Secretary of State of the State of Delaware (the “State Office”). For the avoidance
of doubt, notwithstanding anything to the contrary, “Encumbrances” shall not include the Series A Preferred Contractual
Rights (as defined below).

 

    	 

    	 

    

 

SECTION
1.03         Closing. The closing of the Exchange on the terms and conditions set forth in this Agreement (the
“Closing”) shall take place remotely via the exchange of documents and signatures at 10:00 a.m. EST on the same
date as the closing of the Series B Transaction (the “Closing Date”).

 

SECTION
1.04          Closing Documents and Payments. At the Closing, (a) Pyxis shall deliver to the Company a Stock Power substantially
in the form attached hereto as Exhibit B (the “Stock Power”) duly completed and executed in favor of
the Company (together with the certificate PA0001 representing the Series A Shares), (b) the Company shall then file with the State
Office a Certificate of Elimination of the Series A Preferred Stock, in substantially the form attached hereto as Exhibit C
(the “Certificate of Elimination”); (c) the Company shall then file the Certificate of Designations with the
State Office; and (d) the Company shall then issue and deliver to Pyxis a certificate registered in Pyxis’ name evidencing
the Series A-1 Shares (the Stock Power, together with the Certificate of Elimination, the Certificate of Designations and this
Agreement, the “Transaction Documents”). At the Closing, Pyxis shall also receive an opinion of Morris, Nichols,
Arsht & Tunnell LLP, special Delaware counsel to the Company (“MNAT”), in substantially the form attached
hereto as Exhibit C (the “MNAT Opinion”).

 

ARTICLE
II

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company hereby
represents and warrants the following to Pyxis as of date hereof and as of the Closing Date:

 

SECTION
2.01         Organization and Qualification. The Company is a corporation, duly organized, validly existing and in good
standing under the laws of the State of Delaware, and has the requisite corporate power and authority to own its properties and
to carry on its business as now being conducted. Copies of the Company’s Certificate of Incorporation, as amended (including
the Certificate of Designation for the Series A Preferred Stock, the “Charter”) and Amended and Restated Bylaws
of the Company, as amended (the “Bylaws”), and in each case, all amendments thereto, have been filed as exhibits
to the Company’s SEC Documents (as defined below) and have not been further modified, and except as required by the transactions
contemplated hereby and by the Series B Transaction, the Company has no present intention to modify the Charter and Bylaws. The
Company is duly qualified as a foreign corporation to do business, and is in good standing, in every jurisdiction in which its
ownership of property or the nature of the business conducted and proposed to be conducted by it makes such qualification necessary,
except where the failure to be so qualified or in good standing would not, individually or in the aggregate, have or reasonably
be expected to result in a material adverse effect on the condition (financial or otherwise), prospects, earnings, business or
properties of the Company, whether or not arising from transactions in the ordinary course of business (“Material Adverse
Effect”). For purposes hereof, “SEC Documents” shall mean all reports, schedules, forms, statements, exhibits
(including certifications of the Company’s principal executive and financial officers pursuant to Section 302 and 906 of
the Sarbanes-Oxley Act of 2002 and other documents required to be filed by it with the Securities and Exchange Commission (the
“SEC”) pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), for the twelve (12) months preceding the date hereof (all of the foregoing filed prior to or on the date hereof,
or prior to the Closing Date, and all exhibits included therein and financial statements and schedules thereto and documents incorporated
by reference therein being referred to in this Agreement as the “SEC Documents”).

 

    	2

    	 

    

 

SECTION
2.02         Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter
into and perform its obligations under this Agreement and to issue the Series A-1 Shares in accordance with the terms hereof. The
execution and delivery of this Agreement by the Company and the consummation and performance by the Company of the transactions
contemplated hereby, including, without limitation, the issuance of the Series A-1 Shares and of the shares of Common Stock issuable
upon conversion of the Series A-1 Shares (the “Common Shares” and together with the Series A-1 Shares, the “Securities”),
have been duly authorized by all requisite corporate action. This Agreement has been duly executed and delivered by the Company.
This Agreement constitutes the valid and binding obligation of the Company enforceable against the Company in accordance with its
terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies.

 

SECTION
2.03         Issuance of Shares. The Series A-1 Shares and the Common Shares are duly authorized and, upon issuance in
accordance with the terms hereof and the Certificate of Designations set forth on Exhibit A hereto, (i) will be (A) validly
issued, fully paid and non-assessable and (B) free from all taxes, liens and charges in the United States of America with respect
to the issuance thereof, other than any liens or encumbrances created by or imposed by Pyxis, and not subject to preemptive rights
or other similar rights of stockholders of the Company and (ii) shall be afforded the rights and otherwise be subject to (a) the
provisions of Sections 5.3, 5.4, 5.6, 5.7, 5.8, 6.7 and 6.8 of that certain Stock Purchase Agreement, dated March 5, 2003, between
the Company and Pyxis, as amended, and (b) the Registration Rights Agreement, dated March 5, 2003, between the Company and Pyxis
(the “Series A Preferred Contractual Rights”), which rights shall apply to the Series A-1 Preferred Stock as such provisions
and agreement applied to the Series A Preferred Stock prior to the Exchange. Except for the filing of the Certificate of Elimination
and the Certificate of Designations with the State Office, and any notice prior or subsequent to the Closing that may be required
under applicable state and/or federal securities laws (or comparable laws of any other jurisdiction), no authorization, consent,
approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau,
agency, instrumentality or other third party, is or will be necessary for, or in connection with, the execution and delivery by
the Company of this Agreement, for the offer, issue, sale, execution or delivery of the Series A-1 Shares, or for the performance
by the Company of its obligations under this Agreement. The Company has reserved from its duly authorized capital stock the Common
Shares issuable upon conversion of the Series A-1 Shares.

 

SECTION
2.04         No Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation
by the Company of the transactions contemplated hereby do not and will not (i) result in a violation of the Company’s Charter
or Bylaws; (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
under any agreement, indenture or instrument to which the Company is a party; (iii) result in a violation of any law, rule, regulation,
order, judgment or decree applicable to the Company; or (iv) result in the imposition of a mortgage, pledge, security interest,
encumbrance, charge or other lien on any asset of the Company, except for such conflicts, defaults, terminations, amendments, accelerations,
cancellations, violations and impositions as described in clauses (ii), (iii) or (iv) of this sentence as would not, individually
or in the aggregate, have or result in a Material Adverse Effect.

 

    	3

    	 

    

 

ARTICLE
III

REPRESENTATIONS, WARRANTIES AND COVENANTS OF PYXIS

 

Pyxis hereby represents
and warrants to and agrees with the Company as of date hereof and as of the Closing Date:

 

SECTION
3.01         Title to the Series A Shares. Pyxis owns the Series A Shares beneficially and of record, free and clear of
all Encumbrances. There is no restriction affecting the ability of Pyxis to transfer the legal and beneficial title and ownership
of such Series A Shares to the Company and, upon delivery thereof to the Company pursuant to the terms of this Agreement at the
Closing, the Company will acquire record and beneficial title to such Series A Shares free and clear of all Encumbrances.

 

SECTION
3.02         Pyxis’ Authority to Execute and Perform Agreement. Pyxis has the legal capacity and full legal right
and power and all authority and approval required by law to enter into this Agreement and to perform its obligations hereunder.
Pyxis has duly executed and delivered this Agreement, and this Agreement is the legal, valid and binding obligation of Pyxis enforceable
in accordance with its terms. The execution, delivery and performance of this Agreement by Pyxis does not and will not result in
any violation of or conflict with, or constitute a default under (i) any contract, agreement, document or instrument to which Pyxis
is party or by which Pyxis or any of Pyxis’ properties are bound, or (ii) any law, rule, regulation, judgment or order to
which Pyxis is subject.

 

SECTION
3.03         Accredited Investor. Pyxis is an "accredited investor" as such term is defined in Regulation D
under the Securities Act of 1933, as amended (“Securities Act”).

 

SECTION
3.04         Purchase For Investment. Pyxis is acquiring the Series A-1 Shares for investment for his, her or its own
account and not with a view to the distribution or public offering thereof within the meaning of the Securities Act. Pyxis understands
that the Series A-1 Shares have not been registered under the Securities Act and may not be sold or transferred without such registration
or an exemption therefrom.

 

ARTICLE
IV

CONDITIONS

 

SECTION
4.01         The Company Conditions. The obligations of the Company to issue the Series A-1 Shares on the Closing Date
and to consummate the other transactions contemplated hereby are subject to the satisfaction, on or before the Closing Date (unless
otherwise specified herein), of the following conditions each of which may be waived by the Company in its sole discretion:

 

    	4

    	 

    

 

(a)         Representations
and Warranties. All of the representations and warranties of Pyxis contained in this Agreement shall be true, correct and complete
in all material respects on and as of the date hereof and on and as of the Closing Date, as if made on and as of the Closing Date.

 

(b)         Performance.
Pyxis shall have performed and complied in all material respects with all covenants and agreements contained herein required to
be performed or complied with by them prior to or at the Closing Date, including delivery of the documents set forth in Section
1.04 above.

 

(c)         Filing
and Effectiveness of Certificate of Elimination and Certificate of Designations. The Certificate of Elimination and Certificate
of Designations shall have been filed with the State Office and become effective.

 

(d)         Series
B Transaction Closing. The closing of the Series B Transaction shall occur substantially contemporaneously with the Closing.

 

(e)         Director
Resignation. Effective as of the Closing Date, Catherine Ehrenberger, a designee of the Series A Preferred Stock to the Board
of Directors of the Company, shall have resigned from the Board.

 

(f)         Amendment
to Note Purchase Agreement. The Amended and Restated Note Purchase Agreement , dated March 10, 2009, between the Company and
Pyxis, as amended on August 10, 2009, February 1, 2010 and September 30, 2010, shall have been further amended to extend the Maturity
Date (as defined therein) on which the principal amount of all notes issued thereunder shall be payable to November 30, 2012.

 

SECTION
4.02         Pyxis Conditions. The obligations of Pyxis to consummate the transactions contemplated hereby are subject
to the satisfaction, on or before the Closing Date, of the following conditions, each of which may be waived by Pyxis:

 

(a)         Representations
and Warranties. All of the representations and warranties of the Company contained in this Agreement shall be true, complete
and correct in all material respects, on and as of the date hereof and on and as of the Closing Date, as if made on and as of such
date.

 

(b)         Performance.
The Company shall have performed and complied in all material respects with all covenants and agreements contained herein required
to be performed or complied with by them prior to or at the Closing Date, including delivery of the documents set forth in Section
1.04 above.

 

(c)         Opinion.
Pyxis shall have received the MNAT Opinion from MNAT dated as of the Closing Date.

 

    	5

    	 

    

 

(d)         Series
B Transaction Closing. The closing of the Series B Transaction shall occur substantially contemporaneously with the Closing.

 

ARTICLE
V

MISCELLANEOUS

 

SECTION
5.01         Notices. All notices, requests, consents and other communications hereunder shall be in writing, shall be
addressed to the receiving party’s address set forth below or to such other address as a party may designate by notice hereunder,
and shall be either (i) delivered by hand, (ii) sent by recognized overnight courier, or (iii) sent by registered or certified
mail, return receipt requested, postage prepaid.

 

If to the Company:

 

Interleukin Genetics, Inc.

135 Beaver Street

Waltham, MA 02452

Attention: Chief Financial Officer

 

If to Pyxis:

Pyxis Innovations Inc.

7575 Fulton Street East

Ada, Michigan 49333

Attention: Vice President and General Counsel

 

All notices, requests, consents and other
communications hereunder shall be deemed to have been received (i) if by hand, at the time of the delivery thereof to the receiving
party at the address of such party set forth above, (ii) if sent by overnight courier, on the next business day following the day
such notice is delivered to the courier service, or (iii) if sent by registered or certified mail, on the 5th business day following
the day such mailing is made.

 

SECTION
5.02         Entire Agreement; Previous Agreements. The Transaction Documents embody the entire agreement and understanding
between the parties hereto with respect to the subject matter hereof and supersede all prior oral or written agreements and understandings
relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any kind not expressly
set forth in the Transaction Documents shall affect, or be used to interpret, change or restrict, the express terms and provisions
of this Agreement. Notwithstanding the foregoing, Series A Preferred Contractual Rights shall apply to the Series A-1 Preferred
Stock as such provisions and agreement applied to the Series A Preferred Stock prior to the Exchange.

 

SECTION
5.03         Modifications, Amendments and Waivers. The terms and conditions of this Agreement may be modified, amended
or waived, or consent for the departure therefrom granted, only by written agreement executed by the Company and Pyxis.

 

    	6

    	 

    

 

SECTION
5.04         Assignment. Neither this Agreement, nor any right hereunder, may be assigned by any of the parties hereto
without the prior written consent of the other parties.

 

SECTION
5.05         Parties in Interest. This Agreement shall be binding upon and inure solely to the benefit of each party hereto
and their successors and permitted assigns, and nothing in this Agreement, express or implied, is intended to confer upon any other
person any rights or remedies of any nature whatsoever under or by reason of this Agreement. Nothing in this Agreement shall be
construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded as a third
party beneficiary of this Agreement.

 

SECTION
5.06         Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be construed
in accordance with and governed by the internal laws of the State of Delaware, without giving effect to the conflict of law principles
thereof.

 

SECTION
5.07         Jurisdiction and Service of Process. Any legal action or proceeding with respect to this Agreement shall
be brought in the courts of the Commonwealth of Massachusetts or of the United States of America for the District of Massachusetts.
By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally
and unconditionally, the jurisdiction of the aforesaid courts.

 

SECTION
5.08         Severability. In the event that any court of competent jurisdiction shall finally determine that any provision,
or any portion thereof, contained in this Agreement shall be void or unenforceable in any respect, then such provision shall be
deemed limited to the extent that such court determines it enforceable, and as so limited shall remain in full force and effect.
In the event that such court shall determine any such provision, or portion thereof, wholly unenforceable, the remaining provisions
of this Agreement shall nevertheless remain in full force and effect.

 

SECTION
5.09         Survival. The representations and warranties of the Company and Pyxis contained in Articles II and III, respectively,
shall be deemed to be representations and warranties as of the date hereof and shall survive the Closing and delivery of the Series
A-1 Shares, provided that all such representations and warranties shall terminate three (3) years following the Closing, except
for Section 3.01, which shall survive indefinitely.

 

SECTION
5.10         Headings and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience
of reference only and shall in no way modify, or affect, or be considered in construing or interpreting the meaning or construction
of any of the terms or provisions hereof.

 

SECTION
5.11         Enforcement. Each of the parties hereto acknowledges and agrees that the rights acquired by each party hereunder
are unique and that irreparable damage would occur in the event that any of the provisions of this Agreement to be performed by
the other party were not performed in accordance with their specific terms or were otherwise breached. Accordingly, in addition
to any other remedy to which the parties hereto are entitled at law or in equity, each party hereto shall be entitled to an injunction
or injunctions to prevent breaches of this Agreement by the other party and to enforce specifically the terms and provisions hereof
in any federal or state court to which the parties have agreed hereunder to submit to jurisdiction.

 

    	7

    	 

    

 

SECTION
5.12         Reliance. The parties hereto agree that, notwithstanding any right of any party to this Agreement to investigate
the affairs of any other party to this Agreement, the party having such right to investigate shall have the right to rely fully
upon the representations and warranties of the other party expressly contained in this Agreement and on the accuracy of any schedule
or other document attached hereto or referred to herein or delivered by such other party or pursuant to this Agreement.

 

SECTION
5.13         Expenses. Each of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys,
accountants, appraisers or others engaged by such party) in connection with this Agreement and the transactions contemplated hereby
whether or not the transactions contemplated hereby are consummated.

 

SECTION
5.14         Counterparts. This Agreement may be executed in one or more counterparts, and by different parties hereto
on separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

 

[Remainder of Page Intentionally Left
Blank.]

 

    	8

    	 

    

 

IN WITNESS WHEREOF, the Company and Pyxis
have executed this Agreement as of the day and year first above written.

 

	 	INTERLEUKIN GENETICS, INC.
	 	 
	 	By: 	/s/ Lewis H. Bender
	 	Name: Lewis H. Bender
	 	Title: Chief Executive Officer
	 	 
	 	PYXIS INNOVATIONS INC.
	 	 
	 	By: 	/s/ David J. Tuit
	 	Name: David J. Tuit
	 	Title:  Assistant Treasurer

 

    	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]